Reunion Neuroscience Inc

Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada.

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depression and other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications.

Reunion to Sponsor Scholarships that will Train Healthcare Professionals on Maternal Mental Health Disorders, including Postpartum Depression

Reunion Neuroscience Partners with Seleni Institute on Effective Diagnosis and Treatment of Maternal Mental Health Disorders

MORRISTOWN, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic therapeutic solutions, today announced the appointment of Mark Pollack, M.D., as Chief Medical Officer. Dr. Pollack previously served as a member of Reunion's Advisory Board and is a highly accomplished psychiatrist with decades of leadership experience in neuroscience-focused drug development and clinical research. Pollack replaces Dr. Robert Alexander who will continue to remain involved with Reunion as a strategic advisor.

Reunion Neuroscience Appoints Mark Pollack, M.D., as Chief Medical Officer

Initiative Coincides with Start of Reunion's Phase 2 RECONNECT Study in Postpartum Depression Initiative Coincides with Start of Reunion's Phase 2 RECONNECT Study in Postpartum Depression

Reunion Neuroscience Joins the Is Mom OK? Initiative Recognizing Maternal Suicide Prevention Month

MORRISTOWN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today announced that the first patient has been dosed in the RECONNECT Phase 2 clinical trial of RE104 for the treatment of postpartum depression (PPD). RE104 was designed to be a safe, fast-acting, single-dose therapy to benefit patients suffering from underserved mental health disorders, including PPD.

Reunion Neuroscience Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression

MORRISTOWN, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today announced that the clinical dataset from the Company's Phase 1 study of its lead asset, RE104, will be presented in both a podium and poster at the Anxiety and Depression Association of America (ADAA) Conference taking place April 11-14, 2024, in Boston, MA. The presentations will highlight the Phase 1 findings on RE104, a proprietary, potential best-in-class, patented prodrug of 4-OH-DiPT, a psilocybin-like compound. In a Phase 1 study, RE104 produced a psychedelic, psychoactive state similar in intensity and quality to psilocybin, but lasting only about half the time (3-4 hours) while demonstrating a similar, favorable safety profile. Reunion is evaluating RE104 in patients with underserved mental health disorders, beginning with postpartum depression (NCT06342310).

Reunion Neuroscience Inc. Announces Upcoming Presentations at the Anxiety and Depression Association of America (ADAA) 2024 Conference

WILMINGTON, N.C., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today announced that Greg Mayes, Chief Executive Officer, will participate in the following investor conferences. Please contact your representative to schedule a 1x1 meeting with the company.

Reunion Neuroscience Inc. to Participate in October Investor Conferences

WILMINGTON, Del., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 2 study of RE104, a novel serotonergic psychedelic compound, for the treatment of postpartum depression (PPD). The Phase 2 study, the RECONNECT Trial, is a multicenter, randomized, double-blind, parallel-group, active-dose placebo-controlled study, which will evaluate the safety and efficacy of a single subcutaneous dose of RE104 in adult female patients with PPD. The study is expected to begin in Q4 2023 with a targeted data readout in late 2024.

Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate a Phase 2 Study of RE104 for the Treatment of Postpartum Depression

TORONTO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions and MPM BioImpact ("MPM") are pleased to announce the completion of the previously announced plan of arrangement (the "Arrangement") effective today, whereby MPM acquired Reunion in an all-cash transaction valued at approximately US$13.1 million by way of a court-approved plan of arrangement under Section 192 of the Canada Business Corporations Act.

Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement

TORONTO, July 14, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions is pleased to announce that, earlier today, the Ontario Superior Court of Justice (Commercial List) granted a final order approving the proposed arrangement (the "Arrangement") under Section 192 of the Canada Business Corporations Act, with affiliates of MPM BioImpact ("MPM").

Reunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan of Arrangement

TORONTO, July 13, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the “Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, is pleased to announce the voting results of the special meeting of shareholders of Reunion held yesterday, July 12, 2023 (the "Meeting").

Reunion Neuroscience Inc. Shareholders Approve Proposed Plan of Arrangement

Reunion Neuroscience Inc Thursday reported a net loss of $48,492,996 for its fiscal year 2023, even as the company remains upbeat on the development of its psychedelic treatment for postpartum depression. Reunion, formerly known as Field Trip Health & Wellness Ltd, will be going private during the third quarter of this year after agreeing to be acquired by biotechnology investment firm MPM BioImpact for about US$13.1 million, or US$1.12 per share in cash.

Reunion Neuroscience sees $48.5M loss in FY23 ahead of going private

Common Shareholders to Receive Consideration of US$1.12 Per Share in Cash from the Arrangement Agreement with MPM BioImpact; Special Shareholder Meeting Scheduled July 12

Reunion Neuroscience Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Apollomics Inc

Kaixin Auto Holdings

MultiMetaVerse Holdings Ltd

NanoViricides

SciSparc Ltd

Wearable Devices Ltd

Some of the most promising penny stocks are up-and-coming and just just getting started. The world of penny stocks is all about speculating which young firms have the potential to become the next big companies.

The 7 Most Promising Penny Stocks to Buy in June

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Reunion Neuroscience Inc. (NASDAQ: REUN) to affiliates of MPM BioImpact for $1.12 per share in cash is fair to Reunion shareholders. Halper Sadeh encourages Reunion shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns wheth.

REUN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Reunion Neuroscience Inc. Is Fair to Shareholders

Reunion Common Shareholders to Receive Consideration of US$1.12 Per Share in Cash Represents a 43.1% Premium to the 30-Day Volume Weighted Average Price Reunion Presents Encouraging Phase 1 Final Analysis at American Society of Clinical Psychopharmacology Annual Meeting, Enabling Advancement into Phase 2 in 2H 2023 TORONTO, June 01, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or the "Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that it has entered into a definitive arrangement agreement dated May 31, 2023 (the "Arrangement Agreement") with MPM BioImpact (“MPM”), a world-leading biotechnology investment firm, whereby affiliates of MPM would acquire Reunion in an all-cash transaction valued at approximately US$13.1 million by way of a statutory plan of arrangement under the Canada Business Corporations Act (the "Arrangement"). Pursuant to the terms and conditions of the Arrangement Agreement, all holders of outstanding common shares (“Shares”) of Reunion (the "Shareholders") will be entitled to receive US$1.12 in cash for each Share held immediately prior to the effective time of the Arrangement.

Reunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpact

TORONTO, April 25, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that management will host a corporate presentation at the 2023 Bloom Burton & Co. Healthcare Investor Conference being held on April 25-26 at the Metro Toronto Convention Centre in Toronto, Ontario, Canada.

Reunion Neuroscience Announces Presentation at 2023 Bloom Burton & Co. Healthcare Investor Conference

TORONTO, April 25, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that on April 19, 2023, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“NASDAQ”) indicating that, based upon the closing bid price of the Company's common shares for the 30 consecutive business day period between March 7, 2023, through April 18, 2023, the Company did not meet the minimum bid price of U.S. $1.00 per common share required for continued listing on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of the Company's common shares on the Nasdaq Global Select Market.

Reunion Neuroscience Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

- Seasoned Psychiatrist and Global Pharmaceutical R&D Executive with Over Two Decades of Experience in Clinical Development, Including at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb and Sunovion Pharmaceuticals

Reunion Neuroscience Appoints Dr. Fred Grossman to Board of Directors

Full RE104 Dataset from Phase 1 Study and Overview of Phase 2 Trial to be Featured Full RE104 Dataset from Phase 1 Study and Overview of Phase 2 Trial to be Featured

Reunion Neuroscience Abstract Accepted for Poster Presentation at 2023 ASCP Annual Meeting

TORONTO, March 13, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, has filed a lawsuit today against Mindset Pharma Inc. (“Mindset”) in the United States District Court for the District of New Jersey, alleging that Mindset knowingly copied Reunion's RE104 compound and misleadingly presented that exact composition to the Patent Office as Mindset's invention while applying for U.S. Patent No. 11,591,353 (“‘353 Patent”). Reunion thus seeks to add the original and sole inventor of Reunion's RE104 — Dr. Nathan Bryson, Reunion's Chief Scientific Officer — as an inventor of the ‘353 Patent. Reunion additionally asserts claims for, among others, co-ownership of the ‘353 Patent, inequitable conduct in the prosecution of the ‘353 Patent, and breach of contract. The complaint can be accessed here.

Reunion Neuroscience Files Lawsuit Against Mindset Pharma

TORONTO, March 07, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today announced that management will participate in the Oppenheimer Annual Healthcare Conference as part of the biotechnology virtual corporate presentation on Tuesday, March 14, 2023 at 4:00 PM Eastern Time / 1:00 PM Pacific Time.

Reunion Neuroscience to Participate in the Oppenheimer Annual Healthcare Conference

Reunion Neuroscience Inc. (NASDAQ:REUN ) Q3 2023 Earnings Conference Call February 14, 2023 8:30 AM ET Company Participants Edward Smith - CFO Greg Mayes - President and CEO Robert Alexander - Chief Medical Officer Nathan Bryson - Chief Scientific Officer Conference Call Participants Andrew Partheniou - Stifel Patrick Trucchio - H.C. Wainwright Elemer Piros - EF Hutton Antonia Borovina - Bloom Burton & Co. Sumant Kulkarni - Canaccord Genuity Operator Greetings, and welcome to the Reunion Neuroscience Fiscal Third Quarter 2023 Earnings Conference Call.

Reunion Neuroscience Inc. (REUN) Q3 2023 Earnings Call Transcript

Company Completed Phase 1 Interim Data Analysis for Lead Asset, RE104, Which Showed Strong Safety and Tolerability with Differentiated Profile; Final Data Anticipated in Mid-2023

Reunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023 Financial Results

TORONTO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that the Company plans to release its business update and financial results for Reunion's fiscal 2023 third quarter ended December 31, 2022, before market open on Tuesday, February 14, 2023.

Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday, February 14, 2023, at 8:30 A.M. ET

Field Trip Health & Wellness Ltd

When will capital markets catch up to psychedelic industry? Ronan Levy, CEO and Co-Founder of Field Trip, discusses strategy behind focusing on ketamine assisted therapy.

News for Reunion Neuroscience Inc Stock (REUN)